

Form PTO-1449

(Rev. 8-83)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

2132.031

Serial No.

09/845,729

INFORMATION DISCLOSURE CITATION

FEB 04 2002

(Use several sheets if necessary)

Applicant

Jackowski et al.

Filing Date

04/30/01

Group

1743 1641

U. S. PATENT DOCUMENTS

Examiner Initial	DOCUMENT NUMBER	Date	Name	Class	Subclass	Filing Date if Appropriate
LVC	6 0 2 0 2 0 8	02/01/00	Hutchens et al	436	174	11/27/95
LVC	5 0 6 2 9 3 5	11/05/91	Schlag et al	204	157.41	3/21/89

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation Yes No
LVC WO 98/07036	02/19/98	PCT	G01N	33/68	X
LVC WO 90/14148	11/29/90	PCT	B01D	59/44	
LVC WO 93/24834	12/09/93	PCT	G01N	33/44	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

LVC	Richter et al, Composition of the peptide fraction in human blood plasma: database of circulating human peptides, J. Chrom. B. Biomed. Sci. Appl., 726, 1-2, (1999), pp. 25-35.
LVC	Takahashi et al, Rapid and sensitive immunoassay for the measurement of serum S100B using isoform-specific monoclonal antibody, Clin. Chem., 45, 8, (1999), pp. 1307-1311.

EXAMINER

Olisa. X Cook

DATE CONSIDERED

2/24/03

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



RECEIVED

DEC 10 2002

Sheet 1 of 1

Form PTO-1449
(Rev. 2-88)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
2132.031APPLICATION NO.
09/845,729INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

APPLICANT
JACKOWSKI et al.FILING DATE
04/30/01GROUP
1641

U.S. PATENT DOCUMENTS

EXAMINER'S INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
LVC	5,817,768	10/98	Griening et al.	530	388.1	6/7/95
LVC	5,538,897	07/96	Yates, III et al.	436	80	3/14/94
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
LVC	WO 00/09562	02/00	PCT	C07K	17/00	X
LVC	WO 01/05422	01/01	PCT	A61K	38/17	X
LVC	WO 00/49410	08/00	PCT	G01N	33/53	X
LVC	WO 01/75454	10/01	PCT	G01N	33/68	X

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

LVC		Sobel, et al., "Antipeptide Monoclonal Antibodies to Defined Fibrinogen A α Chain Regions: Anti-A α 487-498, a Structural Probe for Fibrinogenolysis", Blood (1998), Vol. 91, No. 5, pp. 1590-1598.
		Scharfstein, et al., "Usefulness of Fibrinogenolytic and Procoagulant Markers During Thrombolytic Therapy in Predicting Clinical Outcomes in Acute Myocardial Infarction", Am. Journal of Cardiology (1996), Vol. 78, No. 5, pp. 503-510.
		Database Entrez-Protein Online!, "Fibrinogen Alpha", National Center for Biotechnology Information (NCBI), June 15 (2000), Disclosed FPA sequence: aa 20-35, retrieved from www.ncbi.nlm.nih.gov .
LVC		Vaziri, et al., "Factor XIII and its substrates, fibronectin, fibrinogen, and α_2 -antiplasmin, in plasma and urine of patients with nephrosis", J. Laboratory and Clinical Medicine (1991), Vol. 117, No. 2, pp. 152-156.

EXAMINER

Olisa. R. Cook

DATE CONSIDERED

2/23/03

* EXAMINER: Initial if a citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

① abstract: considered LVC 2/24/03